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Background: Dengue has emerged as the most significant of arboviral diseases in the 21st century. It is endemic
to >100 tropical and sub-tropical countries around the world placing an estimated 3.6 billion people at risk. It is
caused by four genetically similar but antigenically distinct, serotypes of dengue viruses. There is neither a vaccine
to prevent nor a drug to treat dengue infections, at the present time. The major objective of this work was to explore
the possibility of identifying a small molecule inhibitor of the dengue virus protease and assessing its ability to suppress
viral replication in cultured cells.
Methods: We cloned, expressed and purified recombinant dengue virus type 2 protease. Using an optimized and
validated fluorogenic peptide substrate cleavage assay to monitor the activity of this cloned dengue protease we
randomly screened ~1000 small molecules from an ‘in-house’ library to identify potential dengue protease inhibitors.
Results: A benzimidazole derivative, named MB21, was found to be the most potent in inhibiting the cloned protease
(IC50 = 5.95 μM). In silico docking analysis indicated that MB21 binds to the protease in the vicinity of the active site.
Analysis of kinetic parameters of the enzyme reaction suggested that MB21 presumably functions as a mixed type
inhibitor. Significantly, this molecule identified as an inhibitor of dengue type 2 protease was also effective in inhibiting
each one of the four serotypes of dengue viruses in infected cells in culture, based on analysis of viral antigen synthesis
and infectious virus production. Interestingly, MB21 did not manifest any discernible cytotoxicity.
Conclusions: This work strengthens the notion that a single drug molecule can be effective against all four dengue
virus serotypes. The molecule MB21 could be a potential candidate for ‘hit-to-lead’ optimization, and may pave the way
towards developing a pan-dengue virus antiviral drug.
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Dengue is an arboviral disease which is currently a very
significant global public health concern [1-3]. The dis-
ease is endemic to >100 tropical and sub-tropical coun-
tries. Of the ~3.6 billion people estimated to be at risk
of dengue, ~400 million people experience dengue infec-
tions annually [4]. Four antigenically distinct serotypes* Correspondence: swaminathan@hyderabad.bits-pilani.ac.in
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unless otherwise stated.of dengue viruses (DENV-1, −2, −3 and −4) of the genus
Flavivirus, family Flaviviridae, cause this disease [5].
Clinically, the disease has been distinguished as either
mild dengue fever (DF) or potentially fatal dengue
hemorrhagic fever (DHF) and dengue shock syndrome
(DSS) [6]. Despite decades of efforts, a preventive den-
gue vaccine is not available [7,8]. Ongoing efforts have
revealed the existence of challenging hurdles in dengue
vaccine development [9-11]. This has spurred attention
towards exploring the feasibility of developing thera-
peutic drugs [12,13]. Observations that the virus titers in
DHF/DSS patients are an order of magnitude higher in
comparison to DF patients [14,15], suggest that a drugis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion may be able to prevent the progression of DF to
DHF/DSS.
The DENV genome is a single-stranded positive
sense, ~11 kilobases (Kb) long RNA molecule [5]. It
carries a 5’ cap, but no poly A tail and contains a single
large open reading frame (ORF) sandwiched between two
non-translated regions located at either end. The ORF is
translated in the infected host cell cytoplasm into >3000
amino acid (aa) residue long polyprotein precursor. Co-
and post-translational processing of this precursor by host
and viral proteases generates ten viral proteins, of which
three are structural and the rest, non-structural (NS) pro-
teins [5]. One of these latter proteins, NS3, by virtue of its
function as the viral protease is crucial in the polyprotein
maturation process [16]. The protease activity of NS3, lo-
cated in the N-terminal one-third of the full-length mol-
ecule, contains the classic catalytic triad seen in serine
proteases and relies on cofactor function, mapping to a
hydrophilic 40 aa residue domain of another viral protein,
NS2b [17]. Mutations in either component of the flaviviral
protease that compromise its function lead to abrogation
of replication [18,19]. This two component protease,
NS2b-NS3Pro, has emerged as a potential antiviral drug
target in recent years [16].
Ideally, a DENV inhibitor must be effective against all
four DENV serotypes. This is because, each of the four
DENVs can cause the full spectrum of dengue disease,
and all four DENV serotypes tend to co-circulate in
hyperendemic regions [2,3]. Functional profiling studies
indicate that the NS2b-NS3Pro of the four DENV sero-
types share very similar peptide substrate structure activ-
ity relationships [20]. Based on this notion, we have
explored the feasibility of identifying an inhibitory mol-
ecule with pan-DENV-specificity by empirical screening
of an ‘in-house’ library of ~1000 small molecular weight
compounds. This paper presents the identification of a
DENV-2 NS2b-NS3 protease (NS2b-NS3Pro)-inhibitory
molecule which could inhibit the replication of all four
DENV serotypes in infected cells in culture.
Results and discussion
Recombinant DENV-2 NS2b-NS3Pro
We cloned and expressed DENV-2 protease in E. coli
and purified it to >90% homogeneity using modifications
of previously reported methods [20-22]. The design of a
synthetic NS2b-NS3Pro gene, its expression in E. coli
and its purification by Ni2+-NTA affinity chromatog-
raphy are summarized in Additional file 1: Figures S1
and S2. Using the synthetic fluorogenic peptide Benzoyl-
Nle-Lys-Arg-Arg-4-methylcoumarin-7-amide (Bz-nKRR-
AMC), which has been shown to be a better substrate
compared to peptides containing endogenous dengue
cleavage sites [20], we confirmed that our purifiedDENV-2 NS2b-NS3Pro is enzymatically active based on
the increase in fluorescence that accompanies peptide
cleavage (Figure 1). Assay conditions were optimized to
identify enzyme and substrate concentration ranges com-
patible with a linear dose–response (Figures 1A, and B).
To validate this assay for inhibitor screening, we tested the
effect of the protease inhibitor aprotinin, on the catalytic
activity of DENV-2 NS2b-NS3Pro enzyme. Aprotinin is a
serine protease inhibitor which can bind NS2b-NS3
strongly [20], and inhibit it effectively at nanomolar con-
centrations [21]. Our data showed that aprotinin inhibited
the recombinant protease activity effectively (IC50 = 20nM;
Figure 1C).
Compound MB21 inhibits DENV-2 NS2b-NS3Pro
With a functionally validated DENV NS2b-NS3pro assay
in hand, we next proceeded to screen an ‘in-house’ li-
brary of ~1000 small molecular weight compounds to
identify potential inhibitors. Recent work has shown that
this library contains antimicrobial compounds [23,24].
An initial screen wherein these compounds were tested
at a single concentration (25 μM), identified 25 com-
pounds which manifested >80% inhibition of the recom-
binant NS2b-NS3Pro. One of these, a benzimidazole
compound, MB21, was the most potent, manifesting an
IC50 of 5.9 μM against the recombinant DENV-2 NS2b-
NS3pro enzyme (Figure 2A). Three additional benzimid-
azole compounds, RB02, RA14 and RA16, also inhibited
the cloned DENV-2 protease, albeit at comparatively
lower efficiency (Additional file 1: Figure S3). We used
in silico molecular docking to understand how MB21
may interact with DENV-2 NS2b-NS3Pro. This analysis
showed that MB21 bound to the DENV- protease with
its benzimidazole moiety embedded well within the
hydrophobic cleft of an allosteric site [25], in the vicinity
of the catalytic triad, as depicted in Figure 2 (panels B
and C). Features of MB21 binding observed here correl-
ate with earlier reports on allosteric binding [25,26]. To
understand better the mechanism of action of MB21 on
DENV-2 NS2b-NS3Pro, we determined the efficiency of
protease action over a range of substrate concentrations
in the absence and presence of varying MB21 concentra-
tions (Figure 3A). These data were analyzed using
Lineweaver-Burke double reciprocal plot (Figure 3B).
We observed that both the kinetic parameters, Km and
Vmax, were changed by MB21. These data lead to the
conclusion that MB21 may act by as a mixed inhibitor
of DENV-2 NS2b-NS3Pro. This is consistent with the in
silico docking data which show that MB21 binds to an
allosteric site.
As a next step, we sought to assess if MB21 which
inhibited cloned viral NS2b-NS3Pro efficiently had any
inhibitory activity on the parent virus itself. To this end
we used a cell-based assay in which we infected Vero
Figure 1 DENV-2 NS2b-NS3Pro enzyme assay, optimization and validation. (A) Kinetics of NS2b-NS3Pro action as a function of substrate
concentration (at 5nM enzyme). (B) Rate of enzyme catalysis as a function of enzyme concentration (at 10 μM substrate). (C) Activity of the cloned
NS2b-NS3Pro as function of aprotinin concentration (5nM enzyme, 10 μM substrate, 20 min incubation). Activity in the absence of aprotinin was taken
as 100% (RFU = relative fluorescence units).
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tored the effect of the drug on virus replication. How-
ever, before testing MB21 for its DENV inhibitory
potential, we sought to ascertain if this compound mani-
fested any cytotoxicity on Vero cells. Interestingly, we
found that MB21 at concentrations up to 50 μM (in
0.5% DMSO vehicle) did not manifest any discernible
cytotoxicity compared to controls (treated with 0.5%
DMSO). This was essentially the case even at 100 μMMB21
(in 1% DMSO), as evidenced by comparable cell viability
between 100 μM MB21-treated and 1% DMSO-treated
cells, as shown in Figure 4A. It is to be noted, however,
that 1% DMSO by itself, caused ~30% loss of cell viability,
compared to cells that were not treated with DMSO. Based
on these results, we conclude that MB21 up to 100 μM
final concentration does not manifest discernible cytotox-
icity on Vero cells.Figure 2 Inhibition of DENV-2 NS2b-NS3Pro by MB21 and in silico ana
activity of cloned DENV-2 NS2b-NS3Pro as a function of MB21 concentratio
interaction between MB21 and DENV-2 NS2b-NS3Pro. Hydrophobic residue
in the vicinity of the catalytic triad.It has been shown previously that DENV replication in
cultured cells [27,28] and in animal models [29] can be
monitored by determining the levels of the viral antigen
NS1 using immunoassays. Recently we showed that the
levels of NS1 antigen secreted into culture supernatants
of infected cells closely mirror the viral genomic RNA
levels, measured using quantitative RT-PCR, for all four
DENV serotypes [27].
MB21 is a pan-DENV inhibitor
Given the high degree of functional similarity of the
NS2b-NS3Pro enzymes among the four DENV serotypes
[20], we anticipated that MB21 may indeed be capable
of inhibiting the replication of all four DENV serotypes.
To test this, we infected Vero cells with each of the
DENV serotypes separately, in the absence or presence
of MB21 (at 30 μM final concentration), and monitoredlysis of the interaction between the two. (A) Inhibition of protease
n. (B) Computer generated 2D ligand interaction picture depicting the
s are shown in green. (C) Interaction of MB21 at the allosteric pocket
Figure 3 Mode of inhibition of DENV-2 NS2b-NS3Pro by MB21. (A) Enzymatic activity of DENV-2 NS2b-NS3Pro as a function of substrate
concentration in the absence (filled circles) and presence of 6 μM MB21 (empty circles). The table shows kinetic parameters in presence (E + S + I) and
absence (E + S) of MB21. E, S and I denote the enzyme, DENV-2 NS2b-NS3Pro, the substrate, Bz-nKRR-AMC, and the inhibitor, MB21. (B) Lineweaver-Burke
plot of DENV-2 NS2b-NS3Pro activity in the absence (filled circles) and presence of 6 μM MB21 (empty circles). Data were analyzed using
GraphPad Prism software.
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Culture supernatants were withdrawn at regular inter-
vals over a 1 week period and analyzed for NS1 antigen
levels using a commercially available ELISA kit. The data
comparing the kinetics of viral NS1 antigen secretion, by
each one of the DENV serotypes, into the culture super-
natant in the absence and presence of MB21 are pre-
sented in Figure 4 (panels B to E). These results show
that MB21 did indeed causes a statistically significant re-
duction of NS1 antigen levels secreted by all four DENV
serotypes.
If NS1 secretion goes down, mirroring the down-
regulation of viral replication, it follows that final viral
titers must also be reduced in the presence of MB21. To
ascertain this possibility, we measured DENV titers in a
virus yield reduction assay. In this experiment, viralFigure 4 Evaluation of antiviral activity using cell-based assay. (A) His
cell control), 1% DMSO vehicle alone (‘V’) or 10 μM MB21 in 1% DMSO veh
DENV-infected cells. Vero cells were infected with DENV-1 (B), DENV-2 (C), DEN
bars) of MB21. Culture supernatants withdrawn at the indicated time points d
the Dengue NS1 ELISA kit (the NS1 ELISA absorbance scale on the Y-axis
vertical bars represent standard deviation, SD. Two-way ANOVA and Bonf
were either significant (**) or very significant (***).titers in DENV-infected culture supernatants (MB21
treated as well as untreated) harvested at day 3 post-
infection were measured using a standard plaque assay
(Additional file 1: Figure S4). It was seen that at all dilu-
tions of the culture supernatant tested, the number of
plaques in the presence of MB21 was significantly lower
compared to that in the absence of the drug. This ex-
periment was performed with all four DENV serotypes.
The viral titers calculated from the plaque counts are
summarized in Table 1. These data reveal that MB21
could inhibit DENV-1, −2, −3 and −4 titers by 50, 82, 75
and 73%, respectively. This was found to be statistically
significant. The observed reduction in DENV titers
correlates with the decrease in viral antigen synthesis
(Figure 4, panels B-E) and corroborates NS1 as a
marker for DENV replication.togram showing the viability of Vero cells that received no drug (‘CC’,
icle (‘T’). Panels B-E depict the effect of MB21 on NS1 secretion by
V-3 (D) or DENV-4 (E) either in the absence (black bars) or presence (grey
uring the 1 week experiment, were tested for viral antigen levels using
is the same for panels B-E). Data shown are mean values (n = 3). The
erroni post-test analysis was done using GraphPad Prism. P values
Table 1 DENV titersa (x106 pfub/ml) in the absence and
presence of MB21
DENV serotypec Without MB21 With MB21d P valuee
1 1.06 ± 0.03 0.52 ± 0.02 0.0028***
2 1.54 ± 0.12 0.27 ± 0.01 0.0045***
3 0.59 ± 0.01 0.14 ± 0.04 0.0065***
4 0.22 ± 0.02 0.05 ± 0.03 0.031**
aTiters were determined by plaque assay on Vero cells.
bPfu = plaque forming units.
cThe viral strains used were: DENV-1: West Pac 74; DENV-2: S-16803; DENV-3:
CH54389; and DENV-4: TVP-360.
dMB21 used at 30 μM final concentration.
eP values were calculated using Graphpad software; P values were either
significant (**) or very significant (***).
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MB21 is a pan-DENV inhibitor. The precise mechanism
of the pan-DENV inhibitory activity of MB21 needs elu-
cidation. Consistent with protease assay data, prelimin-
ary in silico docking (Figure 2) suggests that MB21 binds
to the protease in the vicinity of its active site. The pos-
sibility that this binding may perturb the recently identi-
fied allosteric site (Ala125) on the protease [30] needs to
be addressed. The likelihood that MB21 may comprom-
ise the ability of NS2b-NS3Pro to recruit fatty acid syn-
thase during productive DENV infection [31] is another
avenue to be explored.Conclusions
The need for dengue drugs is being increasingly felt as
dengue vaccine continues to be elusive. Based on its crit-
ical role in the DENV life cycle, NS2b-NS3Pro has
emerged as a potential antiviral target. We set up and
validated an in vitro DENV protease assay and used it to
initiate a random screening campaign to search an ‘in-
house’ small molecule compound library, from which we
have recently identified molecules with antimicrobial ac-
tion [23,24], for putative pan-DENV inhibitor(s). One
molecule from this library, a benzimidazole compound,
MB21, was a potent inhibitor of the cloned DENV-2
protease, NS2b-NS3Pro (IC50 = 5.95 μM). It appeared to
bind to an allosteric site in the vicinity of the active site.
Examination of steady state enzyme kinetics followed by
double reciprocal plot analysis indicated that MB21 af-
fects both Km and Vmax and presumably functions as a
mixed type inhibitor of NS2b-NS3Pro. Further it did not
manifest significant cytotoxicity at concentrations as
high as 100 μM. Interestingly, MB21 could suppress
NS1 antigen secretion by all four DENVs, suggesting
that it could function as a pan-DENV inhibitor. This
was corroborated by plaque assay data which showed
that viral titers were indeed reduced by MB21 in the
case of each of the four DENV serotypes. The precise
mechanism of action of MB21 on DENV replicationneeds to be elucidated. This molecule may provide a
lead for further optimization.
Methods
Cells, viruses, reagents
The four DENV serotypes used in this study are the
World Health Organization reference strains (DENV-1
West Pac 74, DENV-2 S-16803, DENV-3 CH54389 and
DENV-4 TVP-360) and were kindly provided by Dr. De
Silva, University of North Carolina, USA. The monkey
kidney Vero cell line was from American Type Culture
Collection, Virginia, USA. It was maintained in Dulbec-
co’s Modified Eagle medium (DMEM), supplemented
with 10% (v/v) heat-inactivated (Δ) fetal calf serum
(FCS), in a 10% CO2 humidified incubator, at 37°C.
The synthetic peptide substrate Bz-nKRR-MCA was
custom-synthesized (Peptides International, Louisville,
Kentucky, USA). NS1 ELISA kit was from J. Mitra & Co. Pvt
Ltd, New Delhi, India. MTT (3-(4, 5-dimethylthiazolyl-2)-2,
5-diphenyltetrazolium bromide) assay kit was from
Invitrogen (Life Technologies, USA).
The BITS in-house small molecule library consisted of
diverse small molecules that included benzimidazoles,
benzothiazoles, quinolones, thiazoles, thiazolidines, aze-
tidines and spiropiperidones among others. Details of
synthesis of the benzimidazoles identified as DENV-2
protease inhibitors are provided in Additional file 2.
Protease and protease inhibition assays
Protease assays were carried out in 100 μl volume in mi-
crotiter wells of 96-well plates, essentially as described
earlier [20]. A typical protease reaction (100 μl) con-
tained 5nM purified DENV-2 rNS2b-NS3Pro enzyme
(15 ng protein) in assay buffer (50 mM Tris–HCl,
pH 8.5/1 mM CHAPS/20% glycerol). The reaction was
initiated by the addition of peptide substrate Bz-nKRR-
AMC (10 mM stock) to a final concentration of 10 μM.
The reaction was incubated at 37°C for 20 minutes. Pro-
tease activity was measured in terms of the increase in
fluorescence that accompanied cleavage of the peptide
substrate (λex: 380 nm; λem: 450 nm). Control reactions
in which the protease was omitted were run in parallel
to correct for background fluorescence of the substrate.
To measure protease inhibition, the test compound was
incorporated into the protease reaction prior to sub-
strate addition. Enzyme control (EC) reactions set up in
parallel contained an equivalent amount of the vehicle
(DMSO) without any inhibitor. Half maximal inhibitory
concentration (IC50) was defined as the inhibitor (test
compound) concentration that decreased protease activ-
ity by 50%, with reference to the EC reaction (which was
taken as 100%), under the experimental conditions. All
assays were run in duplicates or triplicates and each ex-
periment was performed at least twice independently.
Raut et al. Virology Journal  (2015) 12:16 Page 6 of 7Vero cell-based DENV inhibition assay
The titers of the stock viruses used were as follows:
DENV-1: 1.6×106; DENV-2: 1.3×106; DENV-3: 1.5×107;
& DENV-4: 1.5×109 PFU/ml. Vero cells were seeded in
48-well plates (4×104 cells/well in 0.5 ml DME +
10%ΔFCS) and incubated for 24 hours (37°C, 5% CO2).
Monolayers were aspirated and treated with 0.5 ml
DME + 0.5% with ΔFCS containing 30 μM final concen-
tration of the test compound. After 1 hour incubation
medium + test compound was removed and saved. The
monolayer was infected with DENV (m.o.i = 0.1; 200 μl/
well in DME + 0.5% with ΔFCS). After 2 hours, the virus
inoculum was removed and replaced with medium con-
taining test compound. The plate was returned to the
incubator. Drug concentration was maintained by the
addition of 5 μl stock compound (equivalent to 30 μM
final concentration) solution into each well on days 3
and 5 post-infection. Aliquots (20 μl) of culture super-
natant were withdrawn at indicated time points up to
7 days for estimation of NS1 antigen by ELISA and viral
titers by plaque assay. Appropriate virus controls (VC)
for each DENV serotype, wherein the drug treatment
was omitted, were run in parallel. All infection experi-
ments were done twice independently. Inhibition by a
test compound was assessed with reference to VC which
was taken to represent 100% infectivity.
DENV NS1 determination
Culture supernatants collected at various time points,
which were stored frozen at −20°C, were thawed and di-
luted appropriately (1:100 to 1:1000 in DME + 0.5%ΔFCS).
Suitable aliquots (50 μl) of this were used to detect DENV
NS1 antigen using a commercially available Dengue NS1
ELISA kit (J. Mitra & Co., India), as per the manufacturer’s
protocol. This kit uses N- and C-terminal domain-specific
anti-NS1 antibodies to detect the NS1 antigen produced
by all four DENV serotypes.
MTT assay
Vero cells were seeded in a 96-well microtiter plate
(5,000cells in 200 μl DME + 5%Δ FBS) were exposed to
different test compounds at a range of concentrations
(2-100 μM) for four days at 37°C in a 10% CO2 incubator.
Control wells received an equivalent amount of DMSO
vehicle without the test compound. Cell viability was
assessed based on the reduction of MTT using a com-
mercial kit as per the manufacturer’s instructions.
Statistical analysis
The statistical significance between MB21-treated and
untreated samples was assessed using GraphPad Prism
v6 for Windows. Differences were considered statistically
significant when the probability levels (P) were <0.05.In silico studies
Molecular docking of MB21 onto the three-dimensional crys-
tal structure of DENV-2 NS2b-NS3Pro (pdb code: 2FOM)
obtained from the protein data bank (www.rcsb.org)
was performed using GLIDE extra precision module
(Glide v5.7, Schrodinger, LLC, New York, NY) as de-
scribed [32].
Additional files
Additional file 1: Supplementary results Figures S1-S4.
Additional file 2: Synthesis of benzimidazoles.
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